Back to results
US 2012/0230993 A1Published application
Axl tyrosine kinase inhibitors and methods of making and using the same
AssigneeThe Regents of the University of Colorado
InventorsDouglas Kim GRAHAM, Susan Louise SATHER
Life of this patent
Estimating the term…
Abstract
Disclosed are novel inhibitors of the Axl receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy.
Claims16
A method of treating cancer in an individual, comprising administering to the individual an Axl fusion protein comprising:
- a) a first protein comprising, consisting essentially of, or consisting of, at least a portion of the extracellular domain of an Axl receptor tyrosine kinase (Axl RTK) that binds to an Axl ligand;
- and
- b) a second protein that is a heterologous fusion protein, wherein the second protein is fused to the first protein.
The Axl fusion protein of any one of the preceding claims, wherein the heterologous fusion protein is an immunoglobulin Fc domain.
Dependencies are inferred from the claim text.